Wednesday, October 26, 2016
Video: Page (1) of 1 - 08/29/12 Email this story to a friend. email article Print this page (Article printing at page facebook
Analyst Moves: LLY, LXK

By DMO Affiliate
Eli Lilly (LLY) had its price target increased by Bank of America/Merrill Lynch due to Ramucirumab's potential as a successful cancer drug. A $52 price target was issued with a buy rating.
Analyst Moves: LLY, LXK

Page: 1


Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines